SDS Optic S.A. continues its development and strengthens its strategic competencies in 2025

At the end of 2024, the Company announced the start of cooperation with Marcin Szuba an experienced business practitioner who has already actively begun working within the company's structures. His activities aim to strengthen the Company's ability to seek and acquire partnerships and investors in Poland and abroad. His responsibilities will also include supporting the efforts of the new team member in the role of Business Development Director.

At the beginning of 2025, Anna Uherek joined the Company as the new Business Development Director, bringing to SDS Optic over 25 years of business and management experience gained in international pharmaceutical corporations and leading research and development organizations (CRO/CDMO). Her expertise includes business development, project management, establishing international collaborations, and extensive knowledge in preclinical research.

After many years of jointly building the Company, SDS Optic S.A. is ending its cooperation with Mateusz Sagan, who has been involved in leading the development of the entire Capital Group for nearly nine years. Within the Company, he held the position of Director of Operations and Business Development. Mateusz Sagan was responsible for operational, business, and financial matters, as well as investment aspects and activities related to the Company’s presence on the stock exchange. Mateusz Sagan remains a shareholder of SDS Optic and will continue to support the further development of the entire Capital Group.

Anna Uherek takes on the position of Business Development Director

On January 1, 2025, Anna Uherek assumed the position of Business Development Director. For years, she has successfully created and implemented business development strategies in the pharmaceutical and biotechnology sectors. Her efforts have focused on building and maintaining long-term relationships with partners in the European and American markets, as well as effectively managing research and development projects.

Between 2015 and 2020, she worked at Selvita, where she actively developed services dedicated to preclinical drug development, particularly in the field of oncology. She then continued her career as a director at leading CRO/CDMO companies, strengthening her position as an expert in preclinical research.

The new Business Development Director is a graduate of the Faculty of Molecular Biology at Jagiellonian University and has also completed an MBA postgraduate program at Teesside University. She regularly participates in international industry conferences as a speaker and business representative. As Business Development Director, Anna Uherek will be responsible at SDS Optic S.A. for developing and implementing business development and commercialization strategies, expanding international cooperation, and securing strategic partnerships.

We are confident that Anna Uherek's extensive experience and her past successes in business development will significantly strengthen our team and contribute to the further dynamic growth of SDS Optic in international markets. – Marcin Staniszewski, CEO of SDS Optic S.A.

The turn of 2024/2025 and the Company's future development plans

"Marcin Staniszewski, CEO also spoke about the future plans of SDS Optic S.A.: The inPROBE technology introduces an innovative and entirely new approach to measuring the concentration of small molecules. From the very beginning, we have been striving to develop our solution in a way that ultimately delivers a safe, fully validated technology to the market—one that addresses the clinical and market demand for molecular tests to support doctors in making targeted diagnoses. We are currently at the stage of clinical trials and intensive efforts toward commercializing the technology. The level of advancement of many internal processes, as well as the dynamically evolving market, requires regular updates to the Company's needs. In light of this, decisions have been made to structure the competencies of the SDS Optic S.A. team, ensuring further consistent and stable growth of our initiatives. At this point, I would like to thank Mr. Mateusz Sagan for his dedication and the years we have spent working together at SDS Optic S.A. I also welcome new team members, including our Business Development Director, Anna Uherek, as well as Marcin Szuba."

We have a lot of work ahead on the path to commercialization. I am confident that the team we have built, supported by new specialists, will enable us to develop the optimal strategy for growth and commercialization—not only for the first inPROBE application in breast cancer but also for every project the Company will undertake.

In the coming months, the Company, in line with previous announcements, plans to focus on several key initiatives: launching the second phase of the clinical trial, implementing projects funded with nearly 6.5 million PLN from the Lublin Agency for Enterprise Support, and carrying out activities related to the financing agreement signed with the European Investment Bank. Our priority is also to transition the Company back to continuous trading on the NewConnect market. Throughout 2025, we will continue working on improving investor relations practices, our quality management system, and the techniques used in R&D processes.